Jaroonvesama N
Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 1991 May;74(5):278-82.
Twenty-three mild and moderate essential hypertensive patients, 3 males and 20 females without any complications were given nitrendipine or Baypress, a new calcium antagonist, 10-20 mg once daily for 23 weeks. The blood pressure of all 23 patients was significantly reduced (p = less than 0.01) in both systolic and diastolic blood pressures. No serious side effects were observed. There were only headache (4 cases), palpitation (2 cases), and paroxysmal ventricular contraction (1 case). No hematological, urinalysis and biochemical changes of kidney and liver functions, fasting blood sugar, cholesterol and triglyceride except for sodium and potassium which were raised and weight reduction was observed. All patients tolerated the drug very well. We conclude that, nitrendipine is safe and suitable for management of mild and moderate uncomplicated essential hypertension.
23例轻、中度原发性高血压患者,其中男性3例,女性20例,无任何并发症,给予硝苯地平或一种新型钙拮抗剂拜心同,每日1次,每次10 - 20毫克,治疗23周。23例患者的收缩压和舒张压均显著降低(p < 0.01)。未观察到严重副作用。仅出现头痛(4例)、心悸(2例)和阵发性室性收缩(1例)。除钠和钾升高以及体重减轻外,未观察到血液学、尿液分析及肝肾功能、空腹血糖、胆固醇和甘油三酯的生化变化。所有患者对该药耐受性良好。我们得出结论,硝苯地平安全且适用于治疗轻、中度无并发症的原发性高血压。